01:41 AM EST, 11/04/2026 (MT Newswires) -- Idorsia's (IDIA.SW) daridorexant received the breakthrough therapy designation from the US Food and Drug Administration for insomnia disorder in patients aged 10 to 18 years. The designation is backed by the results of a phase 2 study, which showed a significant dose-dependent improvement in total sleep time in the overall pediatric population, with pronounced efficacy in patients with neurodevelopmental disorders, the Swiss biopharmaceutical company said Wednesday. The company intends to launch a pediatric phase 3 clinical development program in the second half of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.